Hims & Hers: Institutional Backing Meets Insider Selling Amid Regulatory Catalyst

Hims & Hers navigates insider selling and strong institutional backing. Strong revenue growth meets a key FDA review that could expand its market in July.

The telehealth provider Hims & Hers Health is navigating a complex market narrative, caught between robust institutional support, a wave of insider selling, and a potentially transformative regulatory review. While major asset managers maintain their substantial stakes, the company's own executives have been significant sellers in recent months.

Over the past quarter, company insiders sold shares worth approximately $3.2 million. Chief Operating Officer Michael Chi was responsible for the lion's share of these sales, disposing of nearly 100,000 shares at an average price around $25 in mid-March. Despite this activity, the management team still retains close to a 14 percent ownership stake in the business.

This insider activity stands in contrast to the positioning of large professional investors. Institutional ownership remains high at roughly 64 percent, with industry giants like Vanguard and Invesco actually increasing their holdings. The picture among funds is mixed, however. While GF Fund Management established a new position in the first quarter, it later reduced its stake by over 60 percent. This sustained institutional interest provides a key pillar of support for the stock.

Operationally, the company continues to deliver strong growth. For its most recent quarter, Hims & Hers reported earnings per share of $0.08, handily beating analyst expectations. Revenue surged 28 percent year-over-year to nearly $618 million, supported by a subscriber base that now exceeds 2.5 million paying members. A strategic shift in its fulfillment model is creating some near-term accounting volatility, pushing revenue recognition into the first half of 2026, but this is viewed as a temporary headwind against intact core growth.

A major potential catalyst lies with the U.S. Food and Drug Administration (FDA). Regulators are currently reviewing whether to remove a dozen peptide therapies from a restrictive list. A positive decision would significantly expand the company's addressable market, allowing it to broaden its treatment offerings. Hims & Hers had strategically positioned itself for this opportunity with the acquisition of a peptide manufacturing facility in early 2025. The market has already reacted to the possibility, sending shares up 7 percent in mid-April.

Wall Street's view remains cautiously optimistic. Bank of America analysts raised their price target to $25, citing the company's existing infrastructure that can be efficiently adapted for new products. The broader analyst consensus, however, sits at a "Hold" rating with an average 12-month price target of $31.86.

Investor attention now turns to the regulatory calendar, with the FDA scheduled to continue its review of peptide compounds on July 23 and 24. Until then, the stability of the company's "Autoship" subscription model will be closely watched as a buffer against sector volatility.